Hope E. Uronis - Concepedia

Author

Hope E. Uronis

Duke Medical Center ORCID

Also Known As

H. E. Uronis, H. Uronis, H.E. Uronis, Hope E Uronis, Hope E. Uronis, Hope Elizabeth Uronis, Hope Uronis

668

Publications

5.4K

Citations

H-Index

Concepts

All Affiliations

Duke Medical Center Duke University Duke University Hospital The University of Texas MD Anderson Cancer Center Dana-Farber Cancer Institute

About

Hope E. Uronis is an author at Duke Medical Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	29	1K
2	Health Sciences	8	8	225
3	Public Health	1	1	116
4	Cell Biology	1	1	16
5	Emergency Medicine	1	1	11

Hope E. Uronis

Publications

3.7K

Citations

H-Index

Page 1

	Year	Citations
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer Ronan J. Kelly, Jaffer A. Ajani, Thomas Zander, New England Journal of Medicine	2021	1.6K
Metastatic Pancreatic Cancer: ASCO Guideline Update Davendra Sohal, Erin B. Kennedy, Pelin Cinar, Journal of Clinical Oncology	2020	271
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer Mitesh J. Borad, Shantan Reddy, Nathan Bahary, Journal of Clinical Oncology	2014	186
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial Daniel V.T. Catenacci, Yoon‐Koo Kang, Haeseong Park, The Lancet Oncology OncologyEsophageal CancerGastrointestinal OncologyPathologyImmune Checkpoint Inhibitor	2020	186
Safety at the Time of the COVID-19 Pandemic: How to Keep Our Oncology Patients and Healthcare Workers Safe Pelin Cinar, Timothy Kubal, Alison G. Freifeld, Journal of the National Comprehensive Cancer Network Healthcare Workers SafeSafety SciencePopulation Health SciencesCovid-19 EpidemiologyCovid-19	2020	116
Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? Katia Papalezova, Douglas S. Tyler, Dan G. Blazer, Journal of Surgical Oncology	2012	86
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors James M. Cleary, Caio Max S. Rocha Lima, Herbert I. Hurwitz, Investigational New Drugs OncologySolid TumorsMedicinePharmacotherapyAnti-cancer Agent	2014	74
Radiotherapy in the Treatment of Patients With Unresectable Extrahepatic Cholangiocarcinoma A. Paiman Ghafoori, John W. Nelson, Christopher G. Willett, International Journal of Radiation OncologyBiologyPhysics Surgical OncologyHepatologyRadiation TherapyMedicineHepatobiliary Tumor	2010	64
A Phase II Trial of Bevacizumab plus Everolimus for Patients with Refractory Metastatic Colorectal Cancer Ivy Altomare, Johanna C. Bendell, Karen Bullock, The Oncologist	2011	63
A randomized pilot trial of a videoconference couples communication intervention for advanced GI cancer Laura S. Porter, Francis J. Keefe, Donald H. Baucom, Psycho-Oncology	2016	62

Page 1